Houston Methodist awarded $4M grant to recruit head of Neal Cancer Center

new hire

Houston Methodist has recruited Dr. Daniela Matei, an expert in ovarian and endometrial cancer, to lead the Dr. Mary and Ron Neal Cancer Center. Photo courtesy Houston Methodist.

Armed with a $4 million state grant, the Houston Methodist Academic Institute has recruited a renowned expert in ovarian and endometrial cancer research to lead the Dr. Mary and Ron Neal Cancer Center.

The grant, provided by the Cancer Prevention and Research Institute of Texas, enabled the institute to lure Dr. Daniela Matei away from Northwestern University’s Feinberg School of Medicine in Chicago. There, she is the Diana Princess of Wales Professor in Cancer Research and chief of the Division of Reproductive Science in Medicine.

Matei will succeed Dr. Jenny Chang, who was hired last year to run the Houston Methodist Academic Institute.

At the Neal Cancer Center, located in the Texas Medical Center complex, oncologists work on innovations in cancer research, treatment, and technology. The center opened in 2021 after the Neals donated $25 million to expand Houston Methodist’s cancer research capabilities. It handles about 7,000 new cases each year involving more than two dozen types of cancer.

U.S. News & World Report puts Houston Methodist Hospital at No. 19 among the country’s best hospitals for cancer care, two spots below Chicago’s Northwestern Memorial Hospital. The University of Texas MD Anderson Cancer Center in Houston sits at No. 1 on the list.

Matei’s research related to ovarian and endometrial cancer holds the potential to benefit tens of thousands of American women. The American Cancer Society estimates:

  • 21,010 women in the U.S. will be diagnosed with ovarian cancer, and 12,450 women will die from it.
  • 68,270 women in the U.S. will be diagnosed with endometrial cancer, and 14,450 women will die from it.

Matei is leaving Northwestern in the wake of widespread cuts in federal funding for medical research. The National Institutes of Health (NIH) has canceled or frozen tens of millions of dollars in grants for Northwestern, the Wall Street Journal reports, and the university has been plugging the gaps with its own money.

“The university is totally keeping us on life support,” Matei told the newspaper last year. “The big question is for how long they can do this.”

According to the Wall Street Journal, Matei’s $5 million NIH grant supporting 69 cancer trials has been caught up in the federal funding chaos, so Northwestern stepped in to cover trial expenses such as nurses’ salaries and diagnostic procedures.

Trial participants include some patients with rare, incurable tumors who are undergoing experimental treatments aligned with the genetics of their condition, the newspaper says.

“It’s certainly a life-and-death situation for cancer patients on these trials,” Matei said in 2025.

Matei is among the beneficiaries of more than $15 million in grants approved February 18 by CPRIT’s board. The grants went toward recruiting five cancer researchers to institutions in Texas.

One of those grants, totaling $1.5 million, went to the University of Houston to recruit Akash Gupta, a research scientist at MIT’s Koch Institute for Integrative Cancer Research. The remaining grants went to recruit scientists to The University of Texas at Dallas and The University of Texas Southwestern Medical Center.
From Your Site Articles
University of Houston and MD Anderson researchers are looking to advance early detection methods for ovarian cancer. Photo courtesy UH.

Houston research team lands $1.2M grant for ovarian cancer research

cancer funding

A team from the University of Houston and MD Anderson Cancer Center is working to find early markers for ovarian cancer.

Backed by a $1.2 million Department of Defense grant, a team led by Tianfu Wu, associate professor of biomedical engineering at UH, is studying autoantibodies that target a tumor suppressor gene that's often mutated in cancers and serves as an early marker of ovarian cancer development.

According to UH, the majority of women with ovarian cancer (70 percent and 75 percent) are diagnosed once the cancer has already spread, with the chances of survival below 32 percent. Computational models estimate that detecting ovarian cancer earlier could reduce mortality by 10 percent to 30 percent.

Doctors generally screen for ovarian cancer by measuring the rising amount of a protein known as Cancer Antigen 125 (CA125). However, additional biomarkers are needed to improve sensitivity and to detect cancer cases that are missed by CA125 testing.

“Advancing early detection methodologies is essential to improving patient prognosis and survival outcomes,” Wu said in a news release. “The technological challenges in the early detection of ovarian cancer are multifaceted, primarily due to limited sensitivity of currently available biomarkers and the absence of highly accurate biomarkers that can detect the disease well before clinical diagnosis.”

Wu’s team developed a test that detects thousands of immune reactions simultaneously by searching for immune complexes in an effort to identify new autoantibodies. They found more than 100 significantly upregulated immune complexes in ovarian cancer patients compared to healthy patients.

The team will test 10 to 20 of the biomarker candidates to assess their performance in the early detection of ovarian cancer. They will use machine learning modeling to develop computer algorithms for data analysis and disease predictions as well.

Dr. Robert C. Bast at MD Anderson Cancer Center has pioneered the practice of early detection of ovarian cancer, and is Wu’s partner on a team. Ying Lin, associate professor of industrial and systems engineering at UH, and Dr. Zhen Lu from at UT MD Anderson Cancer Center are also working on the project.

Sentinel BioTherapeutics is developing cytokine interleukin-2 (IL-2) capsules to fight many solid tumors. Photo via Getty Images.

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Booming Houston suburb launches innovation grant to attract startups

innovation incentive

Think you’ve got a burgeoning startup? Consider moving it to southwest Houston. The City of Sugar Land announced the Sugar Land Starts Innovation Fund last week to support companies that move jobs to the area.

“The Sugar Land Starts Innovation Fund is designed to support companies that are ready to grow and make a meaningful, long-term commitment to our community,” Colby Millenbruch, business recruitment manager for the City of Sugar Land, said in a news release. “By focusing on revenue-generating startups and performance-based incentives, we are creating a clear pathway for innovative companies to scale while reenergizing existing office space.”

The performance-based, non-equity dilutive grant program is open to companies that demonstrate at least $250,000 in generated revenue or $500,000 in institutional backing from a bank or venture capital firm. They must commit to hiring or relocating at least three employees in Sugar Land for a minimum of three years and at an average salary of $61,240. Compliance will be verified through Texas Workforce Commission reporting.

The fund builds off the Sugar Land Plug and Play partnership to turn the city into an innovative technology hub.

Collaboration with the Silicon Valley-based startup incubator and accelerator on a physical location in southwest Houston has supported 22 startups and has raised $6.5 million in capital since it officially launched in Sugar Land last March. Companies located at the Sugar Land Plug and Play include Synaps, a browser-based design platform for architects, and Intero Biosystems, which produces miniature human organs for preclinical drug development.

In addition to direct funding and business space, both the new grant and the overall Plug and Play project facilitate meetings with Houston-area businesses like CenterPoint Energy.

This should not only bring new industries to Sugar Land, but also allow existing companies to expand outward as technological investors to create a web of new progress.

“This investment is about more than technology. It’s about creating an environment where innovation can take root, grow, and deliver lasting value for the Sugar Land community,” David Steele, director of Texas at Plug and Play, added in the release. “Sugar Land is setting itself apart by taking a long-term view, investing in founders, partnerships, and technologies that will define the next chapter of growth. We’re proud to partner with the city in building an innovation ecosystem that benefits both entrepreneurs and the broader community.”

Income study shows $100,000 salary goes further in Houston in 2026

Money Talk

A 2026 income study has good news for big earners in Houston: A six-figure salary goes further than it did last year.

A Houston resident's $100,000 salary is worth $84,840 after taxes and adjusted for the local cost of living, according to the new financial analysis from SmartAsset. That's about $1,500 more than Houstonians were bringing home last year.

The 2026 take-home pay is about 8 percent higher than it was in 2024, when the same salary had an adjusted value of $78,089.

SmartAsset used its paycheck calculator to apply federal, state and local taxes to an annual salary of $100,000 in 69 of the largest American cities. The figure was then adjusted for the local cost of living (which included average costs for housing, groceries, utilities, transportation, and miscellaneous goods and services). Cities were then ranked based on where a six-figure salary is worth the least after applicable taxes and cost of living adjustments.

Houston ranked No. 60 in the overall ranking of U.S. cities where $100,000 is worth the least. If the rankings were flipped and the cities were ranked based on where $100,000 goes the furthest, that places Houston in the No. 10 spot nationwide.

Manhattan, New York remains the No. 1 city where a six-figure salary is worth the least. A Manhattan resident's take-home pay is only worth $29,420 after taxes and adjusted for the cost of living, which is 3.10 percent lower than it was in 2025.

SmartAsset determined Manhattan has a 29.7 percent effective tax rate on six-figure salaries. Meanwhile, the effective tax rate on a $100,000 salary in Texas (based on the eight cities examined in the report) is 21.1 percent. It's worth highlighting that New York implements a statewide graduated-rate income tax from 4-10.90 percent, whereas Texas is one of only eight states that don't tax residents' income.

Oklahoma City, No. 69, is the U.S. city in the report where a $100,000 salary stretches the furthest. A six-figure salary is worth $91,868 in 2026, up from $89,989 last year.

This is the post-tax value of a $100,000 salary in other Texas cities, and their ranking in the report:

  • Plano (No. 27): $72,653
  • Dallas (No. 47): $80,103
  • Austin (No. 53): $82,446
  • Lubbock (No. 59): $84,567
  • San Antonio (No. 62): $86,419
  • El Paso (No. 67): $90,276
  • Corpus Christi (No. 68): $91,110
According to the report, getting some "financial breathing room" by making six-figures really depends on where someone lives and what their lifestyle is. For residents living in the 42 states that levy some amount of income tax, their take-home pay dwindles further."And depending on how taxes are filed, reaching a $100,000 income may push a household from the 22 percent to 24 percent marginal tax bracket," the report's author wrote. "Meanwhile, locations with high costs across housing and everyday essentials may be less forgiving to a $100,000 income."

---

This article originally appeared on CultureMap.com.

Rice University partners with astronaut foundation to offer new STEM scholarship

space scholars

Rice University has partnered with The Astronaut Scholarship Foundation (ASF) to offer a new scholarship opportunity for junior or senior STEM majors, beginning this spring.

The prestigious Astronaut Scholarship includes up to $15,000, mentorship, networking and a paid trip to the ASF Innovators Symposium and Gala. The scholarship is funded by the James A. Lovell Jr. Family Endowment, in honor of the late American astronaut and founder of the ASF.

“This scholarship opportunity represents an exciting new avenue for Rice STEM students to synthesize their experiences in courses and research and their commitment to advancing the public good as leaders in their field,” Danika Brown, executive director for the Center for Civic Leadership at Rice, said in a news release. “We are so grateful to the Lovell family and to the foundation for investing in Rice students, and we are confident that the foundation will be impressed with our nominees and that selected students will have a life-changing experience as astronaut scholars.”

The Rice Space Institute and the Center for Civic Learning recently hosted the ASF at the Ralph S. O’Connor Building for Engineering and Science.

At the ASF event, Jeff Lovell—son of James Lovell, who commanded Apollo 13 and flew on Apollo 8—announced the scholarship aimed at Rice STEM students. Charlie Duke, who served as spacecraft communicator for the Apollo 11 Moon landing and as the lunar module pilot for Apollo 16, also spoke at the event.

The ASF awarded 74 scholarships to students from 51 universities across the U.S. last May.

The ASF awarded its first seven $1,000 scholarships in 1986 to pay tribute to the Mercury 7 astronauts. It has since awarded more than $10 million to more than 850 college students.

So far, only students from Texas A&M University and the University of Texas at Austin have received the scholarship in Texas.

View All Listings